X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaboration aims to leverage Nona's proprietary Harbour Mice H2L2 (two light and two heavy chains) platform to accelerate the development of Antibody-Drug Conjugates targeting cancer.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Partner/Sponsor/Collaborator: Boostimmune
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 26, 2024
Details:
Under the agreement, Pfizer obtains right for the global clinical development and commercialization of Nona Biosciences' MSLN-targeted ADC, HBM9033, that specifically targets human MSLN, a tumor-associated antigen (TAA) upregulated in various solid tumors.
Lead Product(s): HBM9033
Therapeutic Area: Oncology Product Name: HBM9033
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: $1,103.0 million Upfront Cash: $53.0 million
Deal Type: Licensing Agreement December 14, 2023
Details:
The collaboration aims to accelerate the process of antibody discovery and drug development based on the Harbour Mice® antibody technology platform of Nona Biosciences.
Lead Product(s): Undisclosed
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Recipient: Evive Biotech
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration December 10, 2023
Details:
Under the collaboration, Lycia will leverage Nona's proprietary Harbour Mice® HCAb fully human antibody transgenic mice platform to discover novel antibodies for its LYTAC protein degrader therapeutics.
Lead Product(s): Undisclosed
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Partner/Sponsor/Collaborator: Lycia Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration December 04, 2023
Details:
Under the collaboration, Nona Biosciences will integrate GeneQuantum's exclusive and innovative iLDC and iGDC platforms, with its Harbour Mice® platform and cutting-edge technologies, to advance the early discovery of next-generation bioconjugates.
Lead Product(s): Bioconjugate
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Recipient: GeneQuantum Healthcare
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 13, 2023
Details:
By harnessing the immense expertise and resources of both companies, the collaboration aims to accelerate the development of innovative therapeutics for immunological disorders with highly unmet needs.
Lead Product(s): Undisclosed
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Ingenia Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 13, 2023
Details:
Under the expanded collaboration, BeiGene will be granted access to Nona Biosciences' proprietary fully human transgenic mice platform Harbour Mice and will extend to the Harbour Mice® HCAb platform to further improve therapeutic antibody discovery efficiency and flexibility.
Lead Product(s): Undisclosed
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: BeiGene
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Expanded Collaboration September 14, 2023
Details:
The collaboration will leverage Nona’s proprietary Harbour Mice® fully human antibody transgenic mice platform for the discovery of fully human monoclonal antibodies in classical two light and two heavy chain (H2L2) format, and heavy chain only (HCAb) formats.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: PharmaEssentia
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 12, 2023
Details:
IMVT-1401 (batoclimab) is a fully human, subcutaneously administered antibody originated from HanAll, which selectively binds to and inhibits the neonatal Fc receptor (FcRn). It has demonstrated high potential as a new treatment option for gMG patients.
Lead Product(s): Batoclimab
Therapeutic Area: Immunology Product Name: IMVT-1401
Highest Development Status: Phase IIIProduct Type: Large molecule
Recipient: Hanall Biopharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 06, 2023
Details:
Under the agreement, Cullinan Oncology will have the exclusive right to develop and commercialize CLN-418/HBM7008 in the U.S. CLN-418/HBM7008 is a B7H4 x 4-1BB bispecific immune activator developed from next-gen HCAb-based multi-specific antibody discovery platform HBICE®.
Lead Product(s): HBM7008
Therapeutic Area: Oncology Product Name: HBM7008
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Cullinan Therapeutics
Deal Size: $588.0 million Upfront Cash: $25.0 million
Deal Type: Licensing Agreement February 13, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
